Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

  • Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that encompasses several clinical entities that range from simple steatosis to steatohepatitis, fibrosis, ESLD, and HCC in the absence of significant alcohol consumption.
  • Nonalcoholic steatohepatitis (NASH) is part of the spectrum of NAFLD and is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis.
  • NAFLD is associated with an increasing prevalence of type 2 diabetes, obesity, and the metabolic syndrome in the US population.
  • NAFLD has become one of the leading causes of liver transplantation in the United States.

-- To view the remaining sections of this topic, please or --

General Principles

  • Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that encompasses several clinical entities that range from simple steatosis to steatohepatitis, fibrosis, ESLD, and HCC in the absence of significant alcohol consumption.
  • Nonalcoholic steatohepatitis (NASH) is part of the spectrum of NAFLD and is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis.
  • NAFLD is associated with an increasing prevalence of type 2 diabetes, obesity, and the metabolic syndrome in the US population.
  • NAFLD has become one of the leading causes of liver transplantation in the United States.

There's more to see -- the rest of this entry is available only to subscribers.